Publications by authors named "Erica Johnston"

Article Synopsis
  • Abemaciclib, a CDK4/6 inhibitor, has shown promise in treating metastatic castration-resistant prostate cancer (mCRPC), potentially shifting treatment approaches similar to its use in breast cancer.
  • In a study involving 44 patients with mCRPC who had previously undergone multiple treatments, the primary goal was to report the objective response rate (ORR), which was found to be 6.8%, with a disease control rate of 45.5%.
  • The treatment was generally well tolerated, with manageable side effects, and provided preliminary evidence supporting CDK4/6 as a therapeutic target in prostate cancer.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigated the safety and effectiveness of abemaciclib, both alone and in combination with other treatments, for patients with previously treated metastatic pancreatic ductal adenocarcinomas (PDAC).
  • The trial compared abemaciclib to standard chemotherapy and found that it did not provide significant improvements in disease control rates (DCR) or progression-free survival (PFS).
  • Ultimately, no treatment combinations moved to the next phase of testing, confirming that abemaciclib is still considered investigational for this type of cancer.
View Article and Find Full Text PDF

Pediatric solid organ transplant recipients (pSOTR) often demonstrate suboptimal vaccine responses and are not included in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine efficacy trials. This population has shown variable humoral immunity following SARS-CoV-2 vaccination, and no studies have assessed cell-mediated responses after SARS-CoV-2 vaccination in pSOTR. SARS-CoV-2-specific interferon-gamma release assay (IGRA), immunoglobulin G (IgG), and receptor-binding domain (RBD)-angiotensin-converting enzyme 2 (ACE2) blocking antibody (Ab) were measured in pSOTR aged 5-17 years after 2-3 doses of SARS-CoV-2 mRNA vaccine.

View Article and Find Full Text PDF

Objective: Explore consumer understanding of the food industry's 2-date labeling system and the relative effectiveness of messages in increasing understanding.

Design: Participant understanding of date labels assessed before and after random assignment to 1 of 7 messages explaining the meaning of the labels.

Setting: US online survey through Amazon Mechanical Turk collected responses from July 29, 2019, to August 5, 2019.

View Article and Find Full Text PDF

Background: Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor administered continuously for hormone receptor-positive (HR), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer. Abemaciclib is associated with dose-dependent early-onset diarrhea. nextMONARCH evaluated abemaciclib monotherapy (with or without prophylactic loperamide) and combined with tamoxifen for endocrine refractory metastatic breast cancer (MBC) after chemotherapy.

View Article and Find Full Text PDF

Retreat from some areas will become unavoidable under intensifying climate change. Existing deployments of managed retreat are at small scale compared to potential future needs, leaving open questions about where, when, and how retreat under climate change will occur. Here, we analyze more than 40,000 voluntary buyouts of flood-prone properties in the United States, in which homeowners sell properties to the government and the land is restored to open space.

View Article and Find Full Text PDF

Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non-small cell lung cancer (NSCLC). A multicenter, nonrandomized, open-label phase Ib study was conducted to test safety, MTD, pharmacokinetics, and preliminary antitumor activity of abemaciclib in combination with other therapies for treatment in patients with metastatic NSCLC. An initial dose escalation phase was used to determine the MTD of twice-daily oral abemaciclib (150, 200 mg) plus pemetrexed, gemcitabine, or ramucirumab, followed by an expansion phase for each drug combination.

View Article and Find Full Text PDF

Purpose: To define the safety, efficacy, and pharmacogenetic and pharmacodynamic effects of sorafenib with gemcitabine-based chemoradiotherapy (CRT) in locally advanced pancreatic cancer.

Methods And Materials: Patients received gemcitabine 1000 mg/m(2) intravenously weekly × 3 every 4 weeks per cycle for 1 cycle before CRT and continued for up to 4 cycles after CRT. Weekly gemcitabine 600 mg/m(2) intravenously was given during concurrent intensity modulated radiation therapy of 50 Gy to gross tumor volume in 25 fractions.

View Article and Find Full Text PDF

Several risk factors have been identified as potential contributors to pancreatic cancer development, including environmental and lifestyle factors, such as smoking, drinking and diet, and medical conditions such as diabetes and pancreatitis, all of which generate oxidative stress and DNA damage. Oxidative stress status can be modified by environmental factors and also by an individual's unique genetic makeup. Here we examined the contribution of environment and genetics to an individual's level of oxidative stress, DNA damage and susceptibility to pancreatic cancer in a pilot study using three groups of subjects: a newly diagnosed pancreatic cancer group, a healthy genetically-unrelated control group living with the case subject, and a healthy genetically-related control group which does not reside with the subject.

View Article and Find Full Text PDF

Background: Patients with advanced hepatocellular (HCC) and biliary tract carcinomas (BTC) have poor prognosis. While the EGFR pathway is overactive in HCC and BTC, single agent anti-EGFR therapies confer modest activity. Preclinical data showed synergistic antiproliferative and proapoptotic effects between anti-EGFR therapies and taxanes.

View Article and Find Full Text PDF

Background: The present study sought to identify couples' cognitive appraisals of breast cancer and the extent to which matched or mismatched appraisals within a couple contribute to distress.

Methods: Women with breast cancer (n = 57) and their partners completed the Cognitive Appraisals of Health Scale along with two self-report measures of distress, the Profile of Mood States and the Impact of Events Scale. Four groups were created based on their cognitive appraisals.

View Article and Find Full Text PDF

Husbands of patients with fibromyalgia syndrome (HFMS) report poorer physical and mental health than husbands of women without illness, as well as role strains because of their wives' condition. There are no published reports regarding the impact of fibromyalgia on their marital relationship. In the present study, we used Lazarus and Folkman's (1984) model of stress and coping as a framework to examine marital satisfaction among HFMS.

View Article and Find Full Text PDF